

CITATION REPORT

List of articles citing

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

DOI: 10.1186/s13075-018-1646-4

Arthritis Research and Therapy, 2018, 20, 155.

Source: <https://exaly.com/paper-pdf/71261477/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	PF-06438179/GP1111: An Infliximab Biosimilar. <i>BioDrugs</i> , 2018 , 32, 639-642	7.9	3
40	TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. <i>AAPS Journal</i> , 2019 , 21, 96	3.7	8
39	A phase III study of BCD-055 compared with innovator infliximab in patients with active rheumatoid arthritis: 54-week results from the LIRA study. <i>Rheumatology International</i> , 2019 , 39, 1537-1546	3.6	5
38	Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1065-1074	5.4	2
37	Biosimilars for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1195-1203	5.203	1
36	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019 , 18, 102404	13.6	3
35	Biosimilars in rheumatology. <i>Pharmacological Research</i> , 2019 , 149, 104467	10.2	2
34	The totality-of-the-evidence approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. <i>Therapeutic Advances in Gastroenterology</i> , 2019 , 12, 1756284819852535	4.7	6
33	Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. <i>RMD Open</i> , 2019 , 5, e000876	5.9	14
32	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019 , 51, 632-639	3.3	22
31	Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion. <i>Drugs in R and D</i> , 2019 , 19, 127-140	3.4	
30	Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 31-40	6.1	48
29	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020 , 34, 27-37	7.9	19
28	Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. <i>BioDrugs</i> , 2020 , 34, 809-823	7.9	10
27	A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade). <i>Drug Design, Development and Therapy</i> , 2020 , 14, 2831-2840	4.4	
26	New era of therapy for endocrine autoimmune disorders. <i>Scandinavian Journal of Immunology</i> , 2020 , 92, e12961	3.4	2
25	A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 876-881	2.3	5

24	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 760-770	2.4	112
23	Are biosimilars approved for use in psoriasis safe enough to replace leading biologic therapies? A review. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 459-466	4.1	3
22	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 744-759	2.4	75
21	Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 483-491	7.1	9
20	Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial. <i>BioDrugs</i> , 2020 , 34, 197-207	7.9	4
19	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 85-99	5.1	8
18	Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 697-704	2.2	3
17	Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 1-13	3.3	1
16	Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 1	1.9	0
15	Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate : A network meta-analysis. <i>Zeitschrift Fur Rheumatologie</i> , 2021 , 1	1.9	0
14	Efectividad y seguridad en el manejo de enfermedades inflamatorias crónicas con medicamentos biosimilares de etanercept e infliximab en pacientes colombianos. <i>Revista Colombiana De Reumatología</i> , 2021 ,	0.2	
13	The response to TNF blockers depending on their comparator in rheumatoid arthritis clinical trials: the lessebo effect, a meta-analysis. <i>Rheumatology</i> , 2021 ,	3.9	0
12	Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020 , 3, e1-e9	0.5	9
11	Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. <i>Journal of Pharmacy Practice and Research</i> , 2021 , 51, 358	0.7	1
10	Fine Comparison of the Efficacy and Safety Between GB242 and Infliximab in Patients with Rheumatoid Arthritis: A Phase III Study. <i>Rheumatology and Therapy</i> , 2021 , 1	4.4	0
9	Biosimilar Monoclonal Antibodies in Latin America.		
8	Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target.. <i>Frontiers in Immunology</i> , 2021 , 12, 782788	8.4	1
7	Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology.. 2022 , 10,		3

- 6 Comparison of Clinical Equivalence of Infliximab and its Biosimilar Combinations with Methotrexate in the Treatment of Rheumatoid Arthritis. *Japanese Journal of Clinical Pharmacology and Therapeutics*, **2022**, 53, 15-24 ○
- 5 Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. *Intestinal Research*, 4-1 1
- 4 Non-Medical Switching in Dermatology: Cost-Conscious Policy or an Affront to Patient Safety?. 1-8
- 3 Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. **2022**, 8, e002423 ○
- 2 Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. **2022**, 8, e002560 ○
- 1 Effectiveness and safety in the management of chronic inflammatory diseases with etanercept and infliximab biosimilars in Colombian patients. **2023**, ○